Buy Pharmaceutical, Biotechnology and Chemical Inventions: World Protection and Exploitation | Law Books , Bioscience Books , science books, A Social Legal Perspective, CHEMISTRY BOOKS

ABOUT THE BOOK

This book highlights the special issues arising in obtaining, commercialising, enforcing or attacking intellectual property rights (including protection of regulatory data) in the pharmaceutical, biotechnology and chemical industries across the world's key jurisdictions. It is unique in presenting topic matter horizontally by subject to facilitate comparison between country practices. The first two chapters give a general introduction to the differences between the jurisdictions and an overview of some of the key concepts in patent law. The remainder of the book is dedicated to a detailed analysis of the major legal issues arising in these areas of technology. Each component chapter has a comparative introduction, looking at the variances in the laws of different domains, followed by side-by-side analysis of the relevant regimes, including tables and flow-charts which summarise and explain the key legal concepts. The jurisdictions covered are the United States, Europe (UK, Germany, Netherlands, France and Italy), Japan, Canada, Australia, India and China.

TABLE OF CONTENTS

Part A. Introduction and Overview
Part B. Fundemental Concepts
1:Overview
2:International treaties
3:Skilled addressee
4:Interpretation of patent claims and specifications
5:Inventorship
6:Ownership
Part C. Obtaining patent rights
1:Overview
2:Drafting bioscience patents
3:Drafting pharmaceutical patents
4:Overview of procedure from filing to grant
5:Types of examination and when to use them
6:Prosecution strategies
7:Types of application and their use
8:Disclosure of information to the patent offices
Part D. The period of the monopoly
1:Overview
2:The patent term, renewal fees, withdrawals, cease & lapse
3:Extensions of term and supplementary protection certificates
Part E. Patent validity
1:Overview
2:Patent validity
3:Priority dates
4:Novelty
5:Grace period
6:Inventive step
7:Enablement/internal fair basis
8:Full description/stuffiness/written description
9:Utility
10:Indefiniteness
11:Secret use before prior date
12:Unity of invention
13:Fraud and misrepresentation
14:Lack of entitlement to the invention
Part F. Amendment
1:Overview
2:When Patents can be added?
3:What amendments are allowable?
4:Amended specifications
Part G. Invalidity proceedings and strategy
1:Overview
2:Third part intervention during prosecution
3:Opposition proceedings
4:Re-examination
5:Revocation/nullification proceedings
6:Declarations of validity
Part H. Infringement
1:Overview
2:Literal infringement
3:Infringement equivalents
4:Contributory infringement
5:Infringement proceedings & strategy
6:Remedies for patent infringements
7:Restrictions on remedies
Part I. Defences to infringement
1:Overview
2:Prior secret use
3:Experimental use and clinical trials
4:The bolar exemption
5:Contributory infringement
6:Parallel importing and exhaustion of rights
Part J. Patent litigation strategies
1:Overview
2:Court hierarchies
3:Overview of litigation
4:Preliminary injunctions
5:Split trials
6:Summary judgments
7:Multi-jurisdictional strategy
8:Practicalities of litigation
9:Settlement of litigation
Part K. Interaction between regulatory approval and patents
1:Overview
2:Regulatory bodies and relevant legislation
3:The pharmaceutical regulatory approval process
4:The biologicals regulatory approval process
5:The medical device regulatory approval process
6:The agricultural chemicals regulatory approval process
7:Regulatory filing strategies adopted by innovator companies
8:Regulatory filing strategies adopted by generic companies
9:Other relevant regulatory laws
Part L. Data exclusivity
1:Overview
2:Comparison of data exclusivity with other right
3:New chemical entity data exclusivity periods for pharmaceuticals
4:Other data exclusivity periods for pharmaceuticals
5:Certified (listed) patents and approval of generic drugs
6:Data exclusivity strategies adopted by innovator companies
7:Data exclusivity strategies adopted by generic companies
8:Medical devices, agricultural chemicals and other non-pharmaceuticals
Part M. Competition law
1:Overview
2:Legal basis for IP as an exception to competition (anti-trust) law
3:Technology transfer arrangements (including Block Exemption)
4:Tie-in clauses / Tie-out clauses
5:Licenses which extend beyond patent term
6:Disclosure to industry standard setting organizations
7:Unjustified threats of patent infringement proceedings
8:Competition issues in settlement of litigation
Part N. Other IP rights
1:Overview
2:Competition issues in settlement of litigation
3:Plant breeder's rights
4:Trade marks, passing off and unfair competition
Part O. Commercial arrangements
1:Oveview
2:Research & development collaboration
3:Commercialisation strategies
4:Licensing
5:Assignments
6:IP due diligence
7:Compulsory licenses
8:Compulsory use or acquisition by government
Tables and Figures